ASU, Pfizer Partner on $5M Type 2 Diabetes Biomarker Project | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Arizona State University's Biodesign Institute will lead a study with partners at Pfizer, the Phoenix VA Healthcare System, and the University of Arizona's BIO5 Institute aimed at discovering protein biomarkers to predict cardiovascular disease in people with type 2 diabetes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.